NCT00301756 - Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

December 31, 2012

Conditions

Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Borderline Ovarian Surface Epithelial-Stromal TumorRecurrent Ovarian CarcinomaStage III Borderline Ovarian Surface Epithelial-Stromal TumorStage III Ovarian CancerStage IV Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Ovarian Cancer

Interventions

DRUG

Belinostat

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (4)

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M4N 3M5

Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

University Health Network Princess Margaret Cancer Center P2C, Toronto

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH